Lexaria Bioscience
LEXX
24 hedge funds and large institutions have $1.63M invested in Lexaria Bioscience in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
14% more funds holding
Funds holding: 21 → 24 (+3)
0.29% less ownership
Funds ownership: 0.87% → 0.59% (-0.29%)
18% less capital invested
Capital invested by funds: $2M → $1.63M (-$365K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$406K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$121K |
| 3 |
VF
Virtu Financial
New York
|
+$28.4K |
| 4 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$19K |
| 5 |
Renaissance Technologies
New York
|
+$9.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.01M |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$23.5K |
| 3 |
OC
Oakworth Capital
Birmingham,
Alabama
|
-$4.35K |
| 4 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
-$2.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.74K |
LEXX Hedge Fund Activity: Q3 2025 in Review
24 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2025, worth a combined $1.63M — down 18% from $2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LEXX positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $406K. The largest seller was Sabby Management, exiting entirely with an estimated $1.01M sold.
- 24 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2025, up from 21 in Q2 2025.
- Funds reported $1.63M of Lexaria Bioscience stock for Q3 2025, down 18% quarter-over-quarter.
- 6 funds opened new Lexaria Bioscience positions in Q3 2025 and 3 closed out, a net change of +3 holders.
- The largest Lexaria Bioscience buyer in Q3 2025 was Murchinson, an estimated $406K added.
- The largest Lexaria Bioscience seller in Q3 2025 was Sabby Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2025.